Clinical Trial Update: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

View source ↗

Summary

Olaparib expanded access program for BRCA-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer in Japan is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: PSR Ovarian Cancer With a BRCA Mutation | Status: NO_LONGER_AVAILABLE